The proceeding is based on a study that it slightly increases the risk of heart inflammation among young people. The vaccine remains recommended in more than 30 years, which do not show the same risks.
Le Monde with AFP
The High Authority of Health in France (HAS) has published, Monday, November 8, a notice in which it advises the use of the vaccine From Moderna for children under 30, based on a study that it slightly increases the risk of heart inflammation for this population.
conducted by the Epi-Phare structure, which combines health insurance and the national drug safety agency and health products, the vast study, also published Monday , has focused on People aged 12 to 50 hospitalized in France between May 15 and August 31 for myocarditis – myocardial inflammation, main heart muscle – or pericarditis – inflammation of the pericardium, the membrane that envelops the heart. In all, 919 cases of myocarditis and 917 cases of pericarditis were noted.
Moderna always recommended for more than 30 years
As had been reassembled in pharmacovigilance reports, the results of the French study confirm that Pfizer vaccines, and especially those of Moderna, increase the risk of occurrence of these diseases within seven days after vaccination, And most often in men under 30 years old. In view of these results, the HAS “recommends, for the population under 30 years of age and since it is available, the use of the Pfizer vaccine, whether it is primaCaccination or reminder”.
On the other hand, it recommends that the Moderna vaccine, “whose vaccine efficiency seems slightly better, can be used in primovaccination and for the administration of a half-dose reminder dose in elderly subjects. over 30 years old “. On October 15, the High Authority recommended to use the Pfizer-Biontech vaccine for the recall doses.
Returning-Risk Report Always Favorable
“When the efficacy of vaccines against the serious forms of CVIV-19 (estimated at about 90%) and the existing but infrequent risks of myocarditis and pericarditis, to the favorable evolution, the benefit ratio -risque vaccines is not questioned, “said Mahmoud Zureik, director of the EPI-flagship structure.
The has continues to recommend, for its part, to vaccinate the most widely possible. “The epidemic currently marks a recovery of which it is difficult to predict the evolution, but the winter period that starts with the foreseeable decline in the effectiveness of vaccines in people vaccinated before the summer again recalls the importance of the importance. To obtain the best possible immunization coverage of the entire population, and in particular in people most likely to make a serious form of Covid-19 “, insists the High Authority of Health. It also considers it necessary to “maintain a high level of protection by the administration of a recall dose in the most fragile and most exposed populations to the virus”.
A health defense council is scheduled for Tuesday morning in Paris. In the evening, President Emmanuel Macron will go back to the French again to evoke the health crisis in particular.